MedTrace Logo

Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF

NCT02804204 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-02-07

No results posted yet for this study

Summary

Multicenter, prospective, observational study for evaluating if circulant rheumatoid factor, cyclic citrullinated anti-peptide anti-bodies and albumin can be used as potential predictors in the response to the treatment with anti-TNF in patients with rheumatoid arthritis after 24 weeks of treatment.

Conditions

Interventions

DRUG

Anti-TNF

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02804204 on ClinicalTrials.gov